Hiển thị các bài đăng có nhãn Attack. Hiển thị tất cả bài đăng
Hiển thị các bài đăng có nhãn Attack. Hiển thị tất cả bài đăng

Thứ Bảy, 1 tháng 4, 2017

Scientists use parasite's internal clock to attack sleeping sickness

Trypanosoma brucei is a parasite that causes the deadly sleeping sickness. Scientists have determined the parasite has its own biological clock that makes it more vulnerable to medications in the afternoon.

The parasite that causes deadly sleeping sickness has its own biological clock that makes it more vulnerable to medications during the afternoon, according to international research that may help improve treatments for one of Africa's most lethal diseases.

The finding from the Peter O'Donnell Jr. Brain Institute could be especially beneficial for patients whose bodies can't handle side effects of toxic treatments used to eradicate the parasite. By knowing the optimal time to administer these medications - which can be fatal - doctors hope to reduce the duration and dosage of the treatment and save more lives.

"This research has opened a door," said Dr. Filipa Rijo-Ferreira, first author of the study from the O'Donnell Brain Institute at UT Southwestern Medical Center. "If the same therapeutic effect can be obtained with a lower dose, then it may be possible to reduce the mortality associated with the treatment."

Establishing that parasites have their own internal clock is a key step in finding new ways to treat a variety of parasitic conditions, from sleeping sickness to malaria. While many of these diseases are often not deadly, sleeping sickness has been among the most lethal.

The condition - known formally as African trypanosomiasis - is transmitted through the bite of the Tsetse fly and threatens tens of millions of people in sub-Saharan African countries. After entering the body, the parasite causes such symptoms as inverted sleeping cycles, fever, muscle weakness, and itching. It eventually invades the central nervous system and, depending on its type, can kill its host in anywhere from a few months to several years.

Control efforts have significantly reduced the number of cases over the last decade. However, an unknown number of people still die annually from sleeping sickness as scientists continue seeking a vaccine and alternative treatments to the arsenic-based medications that are occasionally fatal to patients.
Dr. Joseph S. Takahashi, who oversaw the collaborative study published in Nature

Microbiology with Dr. Luisa Figueiredo at the University of Lisbon in Portugal, said the finding will likely apply to all types of parasites and perhaps lead to improved treatment for their associated conditions.



"There have been many observations of the presence of daily patterns in parasites, but until now we didn't know if this was the result of an intrinsic molecular clock. In the future, we may consider biological rhythms when defining therapies to treat sleeping sickness and potentially other infections," said Dr. Takahashi, Chairman of Neuroscience at UT Southwestern, holder of the Loyd B. Sands Distinguished Chair in Neuroscience, and Investigator with the Howard Hughes Medical Institute.

Researchers from UT Southwestern and the Institute of Molecular Medicine at the University of Lisbon in Portugal made their finding after isolating the parasite - known as Trypanosoma brucei - in the lab and obtaining a type of genetic fingerprint to gauge its daily cycles independent of a host. They found the parasite has daily metabolic cycles that make it more vulnerable to treatments in the afternoon.

Scientists now hope to learn what drives the parasite's internal clock so they can target specific genes and disrupt its circadian rhythms. Much like humans struggle to cope when their sleep cycle is interrupted, scientists expect the parasite would become weaker if its cycle is disturbed.

"We know that in other organisms if we mutate their clock they are less adapted to the world," said Dr. Rijo-Ferreira, an HHMI Associate. "We're trying to jetlag these parasites, trying to make them less fit."

5 parasite diseases to watch for in the U.S.

While deadly sleeping sickness is primarily transmitted in rural regions of Africa, millions of people in the U.S. are exposed to other forms of parasitic diseases. Here are five such diseases the U.S. Centers for Disease Control and Prevention lists as public-health priorities.

Chagas: This disease is most commonly acquired through contact with the feces of an infected kissing bug, a blood-sucking insect. There may be swelling where the parasite enters the body, and in rare cases the disease results in life-threatening inflammation of the heart or brain. If untreated, infection is lifelong. CDC estimates about 300,000 people in the U.S. have the condition.

Toxoplasmosis: This condition is a leading cause of death related to food-borne illness in the U.S. More than 30 million Americans carry the parasite, though few show symptoms because their immune systems protect against the illness. People can become infected by eating undercooked, contaminated meat, and women who are infected during pregnancy sometimes pass the parasite to their unborn children. This transfer can result in a miscarriage, a stillborn child, eye disease, or unusual head size.



Toxocariasis: Caused by two species of roundworm and is typically spread through the feces of dogs and cats. Most infected people don't show symptoms, though in some cases the parasite can travel through parts of the body such as the liver, lungs, or central nervous system. The larvae can also travel to the eye and cause blindness. Each year about 70 people, mostly children, are blinded by the condition.

Cysticercosis: Spread through ingesting larval cysts of a tapeworm, causing infections in the muscles, brain, or other tissue. People become infected when they drink water or eat food contaminated with tapeworm eggs, or if they put contaminated fingers in their mouths. Cysts in the brain or spinal cord commonly cause seizures or headaches. The condition may also cause life-threatening brain swelling or strokes. CDC estimates that at least 1,000 people are hospitalized each year with the more severe brain-related form of the disease.

Trichomoniasis The parasite that causes trichomoniasis is transferred from human to human during sex. About 3.7 million people in the U.S. have the condition, though most do not know they have it. Symptoms may include itching, burning, redness or soreness in the infected areas. The parasite can be eradicated through medications. Without treatment, the infection can last for months or years.

Source: Nature Microbiology - Provided by: UT Southwestern Medical Center

YOUR INPUT IS MUCH APPRECIATED! LEAVE YOUR COMMENT BELOW.

Thứ Năm, 23 tháng 3, 2017

Viruses Created to Selectively Attack Tumor Cells

The image shows tumor cells infected by the virus, which expresses a fluorescent protein. Over the days (in the image fifth day), the virus multiplies, generating new virus that infect more cancer cells

It is an innovative approach that takes advantage of the different expression profiles of certain proteins between tumor and healthy cells that make the virus to only infect the first ones.



Scientists at the IDIBAPS Biomedical Research Institute and at the Institute for Research in Biomedicine (IRB Barcelona) lead a study in which they have designed a new strategy to get genetically modified viruses to selectively attack tumor cells without affecting healthy tissues. The study, published today by the journal Nature Communications, is part of Eneko Villanueva's work for his PhD and it is co-lead by Cristina Fillat, head of the Gene Therapy and Cancer Group at IDIBAPS, and Raúl Méndez, ICREA researcher at IRB Barcelona.

Conventional cancer treatment may cause undesirable side effects as a result of poor selectivity. To avoid them it is important that new therapies can efficiently remove cancer cells and preserve the healthy ones. One of the new approaches in cancer therapy is based on the development of oncolytic viruses, ie, viruses modified to only infect tumor cells. In recent years several studies have been focused on the development of viruses created by genetic engineering to maximize their anticancer effect but, as their potency increases, so does the associated toxicity. Limiting this effect on healthy cells is now the key for the application of this promising therapy.



An innovative and specific approach
In the study published in the journal Nature Communications, researchers from IDIBAPS and IRB Barcelona have developed an innovative approach to provide adenovirus with high specificity against tumor cells. "We have taken advantage of the different expression of a type of protein, CPEBs, in normal and tumor tissues," explains Raúl Méndez from IRB Barcelona.

CPEB is a family of four RNA binding proteins (the molecules that carry information from genes to synthesize proteins) that control the expression of hundreds of genes and maintain the functionality and the ability to repair tissues under normal conditions. When CPEBs become imbalanced, they change the expression of these genes in cells and contribute to the development of pathological processes such as cancer. "We have focused on the double imbalance of two of these proteins in healthy tissues and tumors: on the one hand we have CPEB4, which in previous studies we have shown that it is highly expressed in cancer cells and necessary for tumor growth; and, on the other hand, CPEB1, expressed in normal tissue and lost in cancer cells. We have taken advantage of this imbalance to make a virus that only attacks cells with high levels of CPEB4 and low CPEB1, that means that it only affects tumor cells, ignoring the healthy tissues," says Méndez.



"In this study we have worked with adenoviruses, a family of viruses that can cause infections of the respiratory tract, the urinary tract, conjunctivitis or gastroenteritis but which have features that make them very attractive to be used in the therapy against tumors," explains Cristina Fillat. To do this, it is necessary to modify the genome of these viruses. In the study researchers have inserted sequences that recognize CPEB proteins in key regions for the control of viral proteins. Their activity was checked in in vitro models of pancreatic cancer and control of tumor growth was observed in mouse models.

The onco-selective viruses created in this study were very sophisticated, being activated by CPEB4 but repressed by CPEB1. Thus, researchers achieved attenuated viral activity in normal cells, while in tumor cells the virus potency was maintained or even increased. "When the modified viruses entered into tumor cells they replicated their genome and, when going out, they destroyed the cell and released more particles of the virus with the potential to infect more cancer cells," says Fillat. She adds that, "this new approach is very interesting since it is a therapy selectively amplified in the tumor."



Since CPEB4 is overexpressed in several tumors, this oncoselective strategy may be valid for other solid tumors. Researchers are now trying to combine this treatment with therapies that are already being used in clinical practice, or that are in a very advanced stage of development, to find synergies that make them more effective.
Source: Materials provided by the Institute for Research in Biomedicine (IRB Barcelona)

YOUR INPUT IS MUCH APPRECIATED! LEAVE YOUR COMMENT BELOW.

 
OUR MISSION